×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Novartis shutters MorphoSys sites, lays off staff
BioPharma Dive
Novartis shutters MorphoSys sites, lays off staff. The pharma company said it's merging “all portfolio activities” into Novartis, but remains...
6 months ago
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Fierce Biotech
Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years.
8 months ago
Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation
Fierce Pharma
Novartis confirmed Thursday that it's closing down MorphoSys sites in Munich and Boston and planning around 330 layoffs. The company made the...
6 months ago
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
BioSpace
The closures follow Novartis's acquisition of MorphoSys earlier this year. Novartis is closing down sites in Germany and Boston that were picked...
6 months ago
Novartis says 330 jobs hit as it closes MorphoSys sites
Reuters
Swiss pharmaceutical group Novartis (NOVN.S) said on Thursday it was winding up MorphoSys sites in Germany and the United States, affecting 330 jobs.
6 months ago
Bill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys CEO leads revitalized Vor Bio
Endpoints News
Meury comes to Incyte from back-to-back CEO posts at Anthos Therapeutics and Karuna Therapeutics. Both of those biotechs were acquired by large...
2 weeks ago
Pelabresib delay prompts Novartis to close MorphoSys units, 330 jobs hit
FirstWord Pharma
The closures come after Novartis recorded an $800-million impairment in its third-quarter earnings related to the BET inhibitor pelabresib,...
6 months ago
Morphosys’ antibody still shining – for J&J
European Biotechnology Magazine
Johnson & Johnson has announced positive topline results from its Phase 3b APEX study evaluating TREMFYA® (guselkumab) in adults with active psoriatic...
3 months ago
Novartis sheds MorphoSys staff, sites after pelabresib delay
pharmaphorum
Novartis sheds MorphoSys staff, sites after pelabresib delay ... Novartis has said it will shut down two MorphoSys sites in Germany and the US,...
6 months ago
Swiss pharma giant Novartis to close biotech firm Morphosys
SWI swissinfo.ch
Novartis decided in November 2024 to close the Morphosys sites in Germany and the United States by the end of 2025 and integrate all portfolio...
6 months ago